Relevant bibliographies by topics / HIV-infections HIV-infections HIV-1 Antiretroviral therapy / Books
To see the other types of publications on this topic, follow the link: HIV-infections HIV-infections HIV-1 Antiretroviral therapy.

Books on the topic 'HIV-infections HIV-infections HIV-1 Antiretroviral therapy'

Author: Grafiati
Published: 4 June 2021
Last updated: 4 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 books for your research on the topic 'HIV-infections HIV-infections HIV-1 Antiretroviral therapy.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse books on a wide variety of disciplines and organise your bibliography correctly.

1

P, Flaherty John, and Taiwo Babafemi O, eds. Contemporary diagnosis and management of HIV/AIDS infections. 3rd ed. Newtown, Pa: Handbooks in Health Care Co., 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

P, Flaherty John, ed. Contemporary diagnosis and management of HIV/AIDS infections. 2nd ed. Newtown, Pa: Handbooks in Health Care, 2003.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Bartlett, John G. 2007 Medical management of HIV infection. 2nd ed. Baltimore, MD: Johns Hopkins Medicine, Health Publishing Business Group, 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

HIV and liver disease. New York: Springer, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Subdivision, Namibia Ministry of Health and Social Services Directorate of Special Programmes Response Monitoring &. Evaluation. Report on the 2010 HIV drug resistance survey: Population-based monitoring of HIV drug resistance emerging during treatment and related programme factors in sentinel antiretroviral therapy sites in Namibia. Windhoek: Directorate of Special Programmes, Response Monitoring & Evaluation Subdivision, 2013.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Kalanzi, Dorothy J. AIDS crisis control in Uganda: The use of HAART. Amherst, NY: Cambria Press, 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

World Health Organization (WHO). Monitoring equity in access to AIDS treatment programmes: A review of concepts, models, methods and indicators. Geneva: World Health Organization, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

World Health Organization. Regional Office for South-East Asia. Strategic considerations for scaling up antiretroviral therapy for children living with HIV/AIDS in South-East Asia: Guidelines for programme managers. New Delhi: World Health Organization, Regional Office for South-East Asia, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Namibia. Ministry of Health and Social Services. Directorate of Special Programmes. Response Monitoring & Evaluation Subdivision. Report of the 2006 Namibia HIV Drug Sensitivity Survey. Windhoek, Namibia: Directorate of Special Programmes, Division Expanded National HIV/AIDS Coordination, Subdivision: Response Monitoring & Evaluation, 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Swan, Tracy. Care and treatment for hepatitis C and HIV coinfection: Expanding access through the Ryan White CARE Act. Rockville, MD: U.S. Department of Health and Human Services, Health Resources and Services Administration, HIV/AIDS Bureau, 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
11

Tume ya Kudhibiti Ukimwi Tanzania. Mada zinazojitokeza katika mwitikio wa kupambana na VVU na UKIMWI: Maswali na majibu. Dar es Salaam: Tanzania Commission for AIDS, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
12

Chomba, Chrispin. Antiretroviral therapy community preparedness: Best practices in three selected countries in Southern Africa. Avondale, Harare, Zimbabwe: SAFAIDS, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
13

World Health Organization (WHO). Management of MDR-TB: A field guide, a companion document to Guidelines for the programmatic management of drug-resistant tuberculosis. Geneva: World Health Organization, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
14

Battling HIV/AIDS: A decision maker's guide to the procurement of medicines and related supplies. Washington, DC: World Bank, 2004.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
15

Berkhout, Ben, Hildegund C. J. Ertl, and Marc S. Weinberg, eds. Gene Therapy for HIV and Chronic Infections. New York, NY: Springer New York, 2015. http://dx.doi.org/10.1007/978-1-4939-2432-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
16

Directorate, Zimbabwe Ministry of Health and Child Care AIDS and TB. Guidelines for antiretroviral therapy for the prevention and treatment of HIV in Zimbabwe. Harare: The National Medicine and Therapeutics Policy Advisory Committee (NMTPAC) and the AIDS and TB Directorate, Ministry of Health and Child Care (MOHCC), 2013.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
17

National AIDS Control Organization (India). Antiretroviral therapy guidelines for HIV-infected adults and adolescents including post-exposure prophylaxis. New Delhi: National AIDS Control Organisation, 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
18

Gupta, Indrani. Treatment-seeking behaviour and the willingness to pay for antiretroviral therapy of HIV positive patients in India. Delhi: Institute of Economic Growth, 2003.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
19

World Health Organization. Regional Office for South-East Asia. Management of HIV infection and antiretroviral therapy in adults and adolescents: A clinical manual. New Delhi: World Health Organization, Regional Office for South-East Asia, 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
20

Henggeller, Michelle. Infections in the HIV Patient. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199976805.003.0055.

Full text
Abstract:
The hallmark of the human immunodeficiency virus (HIV) patient with a cluster of differentiation 4 (CD4) T lymphocyte count below 200 is the development of opportunistic infections. Although the use of antiretroviral therapy (ART) has decreased the incidence of these infections, they continue to be a major case of morbidity and mortality in the patient with HIV. These infections can be respiratory in nature and present with cough or shortness of breath: Pneumocystis pneumonia (PCP), tuberculosis (TB), aspergillosis, and coccidioidomycosis. Neurological infections, which can present with change in mental status, include toxoplasmosis encephalitis (TE), meningoencephalitis, John Cunningham (JC) virus, and progressive multifocal leukoencephalopathy (PML). Gastrointestinal infections, such as Cryptosporidium, present with abdominal pain and diarrhea. Viral changes can result from cytomegalovirus retinitis. Fever or nonspecific symptoms can result from disseminated Mycobacterium Avium complex disease, histoplasmosis, bartonellosis, and cytomegalovirus.
APA, Harvard, Vancouver, ISO, and other styles
21

Antiretroviral Therapy. ASM Press, 2001.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
22

Kannan, Meena, Harrison Taylor, and William Tyor. HIV Infection. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199937837.003.0148.

Full text
Abstract:
This chapter focuses on four common opportunistic infections of the nervous system associated with HIV infection, namely cryptococcal infection, cytomegalovirus infection, progressive multifocal leukoencephalitis, and toxoplasmosis. Essential features of neurobiology, clinical presentation, differential diagnosis, diagnostic workup, clinical management, and outcome are discussed for each condition. Although combined antiretroviral therapy for HIV has generally reduced the incidence of these complications of HIV infection, they remain important considerations, especially in areas in which antiretrovirals are unavailable or have limited availability.
APA, Harvard, Vancouver, ISO, and other styles
23

Pereira, Luis F., Mark Bradley, Harold W. Goforth, César A. Alfonso, Joseph Z. Lux, Esteban Martínez, and Michael P. Mullen. Overview of HIV-Associated Multimorbidities. Edited by Mary Ann Cohen, Jack M. Gorman, Jeffrey M. Jacobson, Paul Volberding, and Scott Letendre. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199392742.003.0047.

Full text
Abstract:
With the advent of effective antiretroviral therapy, persons with access to and engagement in HIV medical care and antiretroviral therapy can live longer and remain healthy with what has become a chronic manageable illness. Despite advances in medical care, without access to HIV medical care and antiretroviral therapy or with access but without viral suppression, persons with HIV still experience opportunistic infections and cancers. This chapter reviews the HIV-associated multimorbidities, including pulmonary manifestations, ophthalmological complications, dermatological manifestations, gastrointestinal and hematological illnesses, as well as HIV-associated malignancies. The proposed mechanisms through which HIV may contribute to premature aging are also discussed.
APA, Harvard, Vancouver, ISO, and other styles
24

Kirchner, Jeffrey T. The Origin, Evolution, and Epidemiology of HIV-1 and HIV-2. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780190493097.003.0002.

Full text
Abstract:
HIV-1 originated in the early 1920s in southern Cameroon and the Democratic Republic of Congo. From Africa, HIV rapidly spread in the late 1960s to the Caribbean and then the United States, Europe, and other areas of the world, leading to the global AIDS pandemic. Both HIV-1 and HIV-2 descended genetically from Simian immunodeficiency virus via cross-species transmission. HIV-1 group M was the first lineage discovered and represents the pandemic form of the virus. Group M consists of nine viral subtypes (A–K), has a widespread distribution, and accounts for approximately 95% of all HIV-1 infections. HIV-2 was not discovered until 1986 and makes up approximately 3% of cases worldwide. It is found mainly in West Africa. The genetic diversity of HIV does not appear to significantly affect viral response to antiretroviral therapy. However, viral diversity continues to present challenges for the development of an effective HIV vaccine.
APA, Harvard, Vancouver, ISO, and other styles
25

Reverse transcriptase inhibitors in HIV/AIDS therapy. Totowa, NJ: Humana Press, 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
26

AIDS, Global Business Coalition on HIV. Access to Treatment in the Private-sector Workplace: The Provision of Antiretroviral Therapy by Three Companies in South Africa (Unaids Best Practice Collection). UNAIDS Office, 2005.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
27

Gail, Skowron, and Ogden Richard C. 1953-, eds. Reverse transcriptase inhibitors in AIDS therapy. Totowa, N.J: Humana Press, 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
28

Medication Adherence in HIV/AIDS. Mary Ann Liebert Inc, 2004.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
29

Sherman, Kenneth E. HIV and Liver Disease. Springer, 2014.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
30

Sherman, Kenneth E. HIV and Liver Disease. Springer, 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
31

1951-, Rehle Thomas, Human Sciences Research Council, South African Medical Research Council., and Education Labour Relations Council (South Africa), eds. HIV-positive educators in South African public schools: Predictions for prophylaxis and antiretroviral therapy. Cape Town: HSRC Press, 2005.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
32

1951-, Rehle Thomas, Human Sciences Research Council, South African Medical Research Council., and Education Labour Relations Council (South Africa), eds. HIV-positive educators in South African public schools: Predictions for prophylaxis and antiretroviral therapy. Cape Town: HSRC Press, 2005.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
33

Kulkarni, Kunal, James Harrison, Mohamed Baguneid, and Bernard Prendergast, eds. HIV medicine. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780198729426.003.0012.

Full text
Abstract:
HIV/AIDS is a dynamic and fast-moving specialty. In the early stages of the HIV pandemic, mortality was high, and treatment was limited to management and prevention of opportunistic infections. More recently, treatment improvements have meant that HIV has been transformed from a fatal condition to a chronic infection, with dramatic improvements in life expectancy. Combined data from clinical trials now show life expectancy similar to the general population among those stable on antiretroviral therapy. Although the prognosis of people living with HIV has improved, 34 million people are estimated to be living with HIV globally, and issues of access to, and retention in, care persist in resource-constrained settings. In the UK, with good access to, and retention in, care, late diagnosis is the main threat to successful treatment outcomes. This chapter presents the evidence that guides current practice in HIV medicine. This evidence largely refers to treatment of HIV-1 infection.
APA, Harvard, Vancouver, ISO, and other styles
34

Hasbun, Rodrigo, Richard Dunham, Joseph S. Kass, Rituparna Das, Karen Nunez-Wallace, Lydia J. Sharp, and Doris Kung. HIV-Associated Neurocognitive Disorders. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780190493097.003.0038.

Full text
Abstract:
HIV causes a chronic form of encephalitis (HIVE) that is clinically characterized by either dementia or mild neurocognitive impairment. Since the introduction of antiretroviral therapy in 1996, the incidence of HIV dementia has decreased by 50%, but the prevalence of mild neurocognitive disorder has increased up to 39%. HIVE is the result of direct microglial infection, interruption of trophic factors, or caused by inflammatory cytokines. HIV enters the brain primarily by the “Trojan horse mechanism”; it is carried by monocytes and lymphocytes that cross the blood–brain barrier. HIV has a predilection for the basal ganglia, deep white matter, and hippocampus, resulting in a subcortical dementia. HIV dementia is a diagnosis of exclusion and other co-infections, cerebrovascular disease, malnutrition, and drug abuse should be ruled out before making the diagnosis. In patients receiving antiretroviral therapy with immunological response, a novel condition termed CD8+ T cell encephalitis was recently described.
APA, Harvard, Vancouver, ISO, and other styles
35

Bolduc, Philip, Navix Order, and Emily Colgate. Epidemiology and the Spread of HIV. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780190493097.003.0001.

Full text
Abstract:
Worldwide, approximately 36 million people are infected with HIV. The number of new infections has been declining in most geographic areas including sub-Saharan Africa due to a larger number of persons receiving antiretroviral therapy (ART) and the uptake of new prevention methods. Prevalence in many areas has either stabilized or gradually increased due to prolonged survival. The US epidemic has remained stable, with approximately 1.2 million persons living with HIV. There are fewer AIDS deaths and approximately 40,000–50,000 new infections yearly, leading to an overall increase in HIV prevalence in the United States. Globally, most new infections are via heterosexual transmission, with more than half of new infections occurring in women. In Europe and the United States, the largest number of new infections is occurring in men who have sex with men. Due to the progressive uptake of ART, mother-to-child transmission has declined significantly throughout the world.
APA, Harvard, Vancouver, ISO, and other styles
36

Progress in AIDS Research. Nova Biomedical Books, 2004.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
37

1969-, Zuniga José, ed. A decade of HAART: The development and global impact of highly active antiretroviral therapy. Oxford: Oxford University Press, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
38

Carrico, Adam W., and Michael H. Antoni. Psychoneuroimmunology and HIV. Edited by Mary Ann Cohen, Jack M. Gorman, Jeffrey M. Jacobson, Paul Volberding, and Scott Letendre. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199392742.003.0021.

Full text
Abstract:
Psychoneuroimmunology (PNI) examines the biological and behavioral pathways whereby psychosocial factors may influence the course of chronic medical conditions, including HIV/AIDS. This chapter summarizes PNI research conducted examining the possible role of negative life events (including bereavement), stress reactivity, personality factors, cognitive appraisals, and affective states (depression) in HIV illness progression. Because much of this research was conducted in the era prior to the advent of effective antiretroviral therapy, important questions remain regarding whether there the associations of psychosocial factors with HIV illness progression are independent of medication adherence and persistence. There is also increasing recognition that chronic viral infections such as HIV have neuropsychiatric effects, and more recent PNI research has focused on studying the bidirectional communication between the immune system and central nervous system in HIV. Future research should focus on obtaining definitive answers to these questions to inform the development of novel approaches for reducing psychiatric symptoms and optimizing health outcomes among persons with HIV.
APA, Harvard, Vancouver, ISO, and other styles
39

Vigil, Karen J. Non-opportunistic Infections. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780190493097.003.0036.

Full text
Abstract:
Lymphocytic interstitial pneumonitis is a common respiratory complication of HIV infection in children but a rare complication in HIV-infected adults. The diagnosis requires histologic confirmation by biopsy. Antiretroviral therapy has been used with success for treatment. Nonspecific interstitial pneumonitis (NSIP) presents with dyspnea, nonproductive cough, and fever in patients with CD4+ T cell counts >200 cells/mm3. The diagnosis of NSIP requires histologic confirmation by biopsy. The optimum treatment remains unclear. The prevalence of pulmonary arterial hypertension (PAH) is higher in HIV-infected patients compared to the general population. Potential therapies for HIV-associated PAH include HIV antiretroviral therapy as well as supportive therapy, including oxygen, diuretics, and anticoagulation.
APA, Harvard, Vancouver, ISO, and other styles
40

Letang, Emilio, Francine Cournos, Dimitri Prybylski, Donn Colby, E. Kainne Dokubo, Chuan-Mei Lee, Julia del Amo, et al. Global Aspects of the HIV Pandemic. Edited by Mary Ann Cohen, Jack M. Gorman, Jeffrey M. Jacobson, Paul Volberding, and Scott Letendre. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199392742.003.0004.

Full text
Abstract:
This chapter presents the complex and diverse nature of the HIV/AIDS epidemic on a global scale, as well as a global epidemiology of HIV. The hardest-hit region of the world is sub-Saharan Africa, where heterosexual transmission dominates. Here the overall rate of new HIV infections has decreased in 25 countries by 50% between 2001 and 2011, coupled with scale-up of antiretroviral therapy and prevention of mother-to-child transmission. The Asia-Pacific region has the second highest burden of HIV in the world and, despite a decline in the annual number of new infections, is also seeing increasing HIV prevalence in high-risk groups. In Europe there is a clear division between the epidemics in eastern and western countries. Although antiretroviral therapy has led to great advances in health in this region, late identification of illness and barriers to care for stigmatized populations are a ubiquitous problem in the European Union. In the United States, despite reasonably good access to care, the incidence of HIV has not declined significantly since the advent of effective treatment. Substantial efforts and new strategies in the United States and the Americas have been developed to meet the goals of prevention and care engagement. The chapter also identifies the work needed to address the nuanced challenges to HIV prevention and treatment in different subpopulations across the world.
APA, Harvard, Vancouver, ISO, and other styles
41

Hull, Mark, and Steven C. Reynolds. HIV in the critically ill. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199600830.003.0291.

Full text
Abstract:
It has been over 30 years since the recognition of the acquired immune deficiency syndrome (AIDS), linked to infection with human immunodeficiency virus (HIV). Opportunistic infections arise in the setting of decreases in the CD4+ T-lymphocyte count. Advances in the safety, and effectiveness of combination antiretroviral therapy (cART) have led to substantial improvements in life-expectancy for individuals accessing successful therapy. As such individuals are likely to be admitted to the intensive care unit (ICU) for conditions un-related to HIV, although presentations due to opportunistic infections and malignancies must be considered in those with previously undiagnosed infection or in those patients non-adherent to cART.. Individuals receiving cART must undergo careful evaluation for potential drug–drug interactions with other medications. Treatment interruption of cART is not generally advised due to risk of rebound viraemia and potential development of resistance.. Immune reconstitution inflammatory syndrome may be considered in those with recent cART initiation.
APA, Harvard, Vancouver, ISO, and other styles
42

Cox, Josephine H., Stuart Z. Shapiro, Liza Dawson, Cynthia Geppert, Andrew M. Siegel, and M. Patricia D’Souza. Vaccines for The Prevention and Treatment of HIV Infection. Edited by Mary Ann Cohen, Jack M. Gorman, Jeffrey M. Jacobson, Paul Volberding, and Scott Letendre. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199392742.003.0032.

Full text
Abstract:
While the HIV/AIDS pandemic continues, the overall incidence of HIV infections has fallen through use of antiretroviral therapy (ART) and multiple prevention modalities. To achieve a durable end to the pandemic and avoid the requirement for daily antiretroviral medication over a lifetime, a safe and effective prophylactic vaccine remains essential. This chapter reviews current advances in prophylactic and therapeutic HIV-1 vaccine strategies and the challenges that lie ahead. Recent success in isolation of potent broadly neutralizing antibodies (bnAbs) from infected individuals, the discovery of mechanisms of bnAb induction, and progress in understanding mechanisms of CD8 T-cell killing of HIV-infected cells and the structure of the HIV envelope trimer have opened new strategies for HIV vaccine design. On the therapeutic front, the persistence of HIV reservoirs remains a formidable obstacle to achieving sustained virological remission in HIV-infected individuals after ART is discontinued. Development of a new generation of immune-based therapeutic agents might contribute to a curative intervention. The chapter closes with an overview of ethical challenges in vaccine development and clinical testing.
APA, Harvard, Vancouver, ISO, and other styles
43

Mugavero, Michael J., and J. Michael Kilby. HIV/AIDS in the Fourth Decade. Edited by Mary Ann Cohen, Jack M. Gorman, Jeffrey M. Jacobson, Paul Volberding, and Scott Letendre. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199392742.003.0002.

Full text
Abstract:
This chapter discusses the maturing HIV/AIDS epidemic, now in its fourth decade, with global scale-up of antiretroviral therapy (ART) and reductions in the number of new HIV cases in many regions in the world. Advances in biomedical prevention with promising clinical trial findings for pre-exposure prophylaxis (PrEP) and microbicides provide a scientific foundation for the prevention of new infections in persons who are HIV uninfected and at risk. Landmark trials identifying the benefits of ART treatment as prevention (TasP) of new HIV infections and demonstrating the benefits of early ART initiation at higher CD4 counts have informed global guidelines. The pendulum has swung back to recommending early ART initiation for all persons living with HIV upon learning of a new diagnosis. However, late diagnosis persists as a formidable challenge, and gaps in engagement in medical care among diagnosed persons, as depicted by the treatment cascade, as well as suboptimal adherence to biomedical prevention and ART threaten the effectiveness of these scientific discoveries. The tools and resources are available to hasten the end of HIV/AIDS around the globe with integration of service delivery to address the medical, psychiatric, psychological, and societal impact the virus poses to individuals and communities living with and at risk for HIV/AIDS.
APA, Harvard, Vancouver, ISO, and other styles
44

Pahuja, Meera, Jessica S. Merlin, and Peter A. Selwyn. HIV/AIDS. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199656097.003.0151.

Full text
Abstract:
In less than two decades, AIDS has been transformed from a rapidly fatal, untreatable illness to a manageable chronic disease. Early in the AIDS epidemic, HIV care and palliative care were inseparable; over time, these two treatment paradigms diverged. In the developed world, and to a lesser but increasing extent in the developing world, decreasing mortality rates have resulted in growing numbers of HIV-infected patients living with the disease for many years. As this long-surviving population increases, the challenges of chronic disease management, an expanding range of co-morbidities, and a process that has been described as ‘accelerated ageing’, have all emerged to present new needs and opportunities for palliative care expertise. Earlier in the epidemic, palliative care for AIDS focused primarily on end-of-life care and pain and symptom management related to the manifestations of AIDS-specific opportunistic infections and malignancies. Currently, pain and symptoms may be related to these as well as other co-morbid chronic diseases which commonly occur in HIV-infected patients, including cardiovascular, pulmonary, renal, hepatic, metabolic, and neurocognitive complications. Attention to these symptoms, quality of life issues, and psychosocial problems in long-surviving patients over many years will be increasingly important to support engagement with care and effective adherence with antiretroviral therapy over time. End-of-life care, while less frequent, also remains important, as patients may still die from AIDS, or even more commonly, from end-organ failure, non-AIDS defining malignancies, and/or other complications of ageing and chronic co-morbid disease. All these converging factors have now resulted in a new need for the re-integration of HIV care and palliative care, both to help HIV-infected patients live better and longer, as well as manage late-stage and end-of-life issues when they emerge.
APA, Harvard, Vancouver, ISO, and other styles
45

(Editor), Erik De Clercq, and Anne-Mieke Vandamme (Editor), eds. Combination Therapy of AIDS (Milestones in Drug Therapy). Birkhäuser Basel, 2004.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
46

(Editor), Giuseppe Barbaro, Franck Boccara (Editor), and Giorgio Barbarini (Editor), eds. Cardiovascular Disease in AIDS. Springer, 2005.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
47

Denis, Blandine, Fanny Lanternier, and Olivier Lortholary. Fungal infections among patients with AIDS. Edited by Christopher C. Kibbler, Richard Barton, Neil A. R. Gow, Susan Howell, Donna M. MacCallum, and Rohini J. Manuel. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780198755388.003.0033.

Full text
Abstract:
Fungal infections are the most common opportunistic infections occurring in HIV-infected patients, though their incidence has decreased dramatically with the introduction of combination antiretroviral therapy (cART). Most cases occur in untreated/non-compliant patients or patients whose multiple antiretroviral regimens have failed. They are a good marker of the severity of cellular immunodepression. Pneumocystis jirovecii pneumonia remains a frequent opportunistic infection in rich resource settings, and cryptococcosis a major problem in the Southern Hemisphere. In endemic areas, infections due to dimorphic fungi are an important group. An exhaustive search for dissemination should be made in HIV-infected patients—at least for those at an advanced stage of immune deficiency. Introduction of cART in combination with antifungal treatment depends on the risk of acquired immune deficiency syndrome (AIDS) progression, and on the risk of cumulative toxicity and the immune reconstitution inflammatory syndrome if introduced too early. Fungal infections remain a problem in the cART era.
APA, Harvard, Vancouver, ISO, and other styles
48

Barnett, Ben J., Lisa Armitige, and Karen J. Vigil. Opportunistic Infections. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780190493097.003.0032.

Full text
Abstract:
The question of when to initiate antiretroviral therapy (ART) in the setting of an acute or ongoing opportunistic infection (OI) has been controversial. The immediate initiation of ART in the presence of an OI may provide better clinical outcomes as the immune system improves. However, rapidly decreasing HIV viral load has been associated with the immune reconstitution inflammatory syndrome, which may lead to further complications in the setting of an OI. There are also questions of increasing pill burden, potential drug–drug interactions, additive toxicity and adverse events, and the more practical problem of continuity of care if ART is started in a hospital setting for a newly diagnosed patient with HIV without established outpatient care already in place. This problem could be particularly troublesome for patients who do not have health insurance or otherwise do not have affordable access to ART in the outpatient setting.
APA, Harvard, Vancouver, ISO, and other styles
49

Clercq, Erik De. Combination Therapy of Aids. Springer, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
50

P, Narain Jai, and Narain Jai P, eds. AIDS in Asia: The challenge ahead. New Delhi: World Health Organization, 2004.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the bibliographies on the topic 'HIV-infections HIV-infections HIV-1 Antiretroviral therapy' for other source types:
Journal articles Dissertations / Theses
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography